All analyses
AI analysis

Nawaloka Hospitals Plc: research report

Moderately overvaluedbearishNov 4, 2026

Evidence points bearish because debt exceeds owners' equity and net profit fell despite higher revenue. The counterweight is a record September gross margin.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • Total debt was LKR 7.2 billion, equal to 111.8% of owners' equity, while operating profit covered finance costs only 1.73 times.
  • September-quarter net profit fell 8.2% even as operating profit rose 6.8%, because LKR 382 million was absorbed below operating profit.
  • The company scores 17 out of 100 on price against book value, earnings and dividends, placing it in the CSE's Overvalued band.

Against this. Gross margin reached 57.5%, the best September result in seven comparable filings.

Operating margin
16.9%
from 17.3% a year earlier
Net margin
7.0%sector 13.0%
from 8.3% a year earlier, revenue +8.9%
Return on equity
16.3%sector 11.2%
full year to Mar 31, 2026
P/E
15.9sector 11.8
earnings Rs 0.75 per share, year to Mar 2026
P/B
2.46sector 1.36
book Rs 4.84 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 4, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Nawaloka Hospitals operates private hospitals, diagnostics, specialist clinical centres and digital health services. The latest quarter showed a healthier core hospital operation, with revenue and operating profit rising, but more finance costs, tax and other below-operating items left less profit for shareholders than a year earlier.

Price performance

At LKR 11.10 on 4 November 2026, NHL had fallen 15.0% over three months, versus a 3.0% fall in the ASPI. The share sits 24.3% of the way up its 52-week range, closer to its annual low than its high, while recent volatility was below its own one-year norm.

The record is uneven: five falls of 15% or more occurred in three years, and the deepest was 44% and remains unrecovered. Liquidity is limited, with a LKR 1 million order more than everything that trades on a typical day, meaning that size represents 166% of median daily turnover.

Valuation

NHL trades at 14.8 rupees for every rupee of trailing profit, above the healthcare peer median of 9.94 times. Its P/B of 2.3 means a buyer pays LKR 2.30 for each rupee of net assets, versus the sector median of 1.23; the latest audited ROE of 16.3% partly supports a premium to book, but not necessarily the full premium to sector earnings multiples.

The CSE-wide valuation score is 17 out of 100, in the Overvalued band. The company's own record is mixed: P/B is more expensive than at 10 of the last 11 year-ends, while P/E is more expensive than at only one. No dividend is on record in the last two years.

A buyer at the current price is relying materially on the latest quarter, which supplied 42.8% of trailing EPS. If that quarter had earned its year-ago net margin, the same price would stand on 13.7 times earnings rather than the current P/E.

News and sentiment

Direct coverage is thin, with two material articles in the past 90 days, both classified positive. Both reported on 19 October that Nawaloka bought a 12.12% holding in Digital Health, the Doc990 operator, for LKR 62.7 million.

The investment is small against Nawaloka's LKR 13.2 billion FY2026 revenue base, at about half a percent of annual sales. Digital Health's reclassification from subsidiary to associate changes its accounting treatment, but the reported articles provide no earnings contribution with which to size the effect on Nawaloka's profit.

Financials

September-quarter revenue rose 8.9% year-on-year and operating profit increased 6.8%, but net profit fell 8.2% to LKR 270 million. The business therefore generated more operating profit but retained less of it for shareholders after finance costs, tax and other items.

Gross margin improved from 56.0% to 57.5%, operating margin eased from 17.3% to 16.9%, and net margin fell from 8.3% to 7.0%. The gross margin was the best September result in seven comparable filings, whereas operating and net margins ranked middling against prior September quarters.

Below-operating charges rose to LKR 382 million from LKR 316 million, explaining the divergence between operating and net profit. Equity increased from LKR 5.9 billion to LKR 6.8 billion year-on-year, while the share count remained 1.4 billion, so the earnings movement was not caused by a change in ordinary shares.

Risks

Funding is the central risk. At FY2026 year-end, debt was LKR 7.2 billion, or 111.8% of owners' equity, and operating profit covered the interest bill only 1.73 times. This leaves a relatively narrow operating buffer before finance costs absorb a larger share of earnings.

Liquidity is also tight: the current ratio was 0.62, meaning the group had 62 cents of short-term assets, including inventory and customer receivables, for each rupee of bills due within a year. Operating cash flow was only 0.44 times operating profit and free cash flow was negative LKR 1.4 billion, so the reported operating profit did not fully arrive as cash after investment spending.

The broader backdrop adds pressure rather than a company-specific event: bond yields edged higher and the rupee had weakened 6.8% year-to-date by end-October. Higher funding costs or imported-cost pressure would matter more to a leveraged hospital operator.

Outlook

As at 4 November 2026, the next defined company event is the interim filing for the quarter ending 31 December 2026, expected between 2 and 14 February 2027. It will show whether the stronger gross margin is translating into shareholder profit after finance costs, or whether the below-operating drag persists.

The contribution from the Digital Health associate is not yet quantifiable from the available disclosure. The data also cannot establish how changes in healthcare regulation or public-sector procurement will affect Nawaloka specifically.

About this report. Generated on Nov 4, 2026 from market data up to Nov 4, 2026, 2 material news articles over 90 days and financials to Sep 30, 2026, and scored 17 of 100 on value (overvalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports